| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.0047 | 0.9 |